The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
In this podcast episode recorded at the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025), Megan Melody, MD, from Tampa General Hospital, spoke with Tycel J. Phillips, […]
In this panel discussion at the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025), Elias Jabbour, MD, leukemia professor at the University of Texas MD Anderson Cancer Center, moderates a discussion on acute lymphoblastic leukemia (ALL) treatment with Aaron Logan, MD, PhD, from the University of California, San Francisco, and Ibrahim T. Aldoss, MD, from the City of Hope.
In this interview from the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025), Sundar Jagannath, MD, professor of medicine at the Icahn School of Medicine at Mount Sinai in New York discusses what cure means in multiple myeloma and why there is an urgent need for a formal definition for it in the field.
The US Food and Drug Administration has approved the menin inhibitor ziftomenib for treatment of relapsed or refractory NMP1-mutated acute myeloid leukemia in adult patients who have no alternative treatment options.
In this interview at the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025), Elias Jabbour, MD, leukemia professor at the University of Texas MD Anderson Cancer Center discussed leading a phase 1/2 trial for the potent menin inhibitor bleximenib, an investigational oral therapy used to treat KMT2A-rearranged or NPM1-mutated acute myeloid leukemia (AML).
Patients with chronic lymphocytic leukemia (CLL) who have a body mass index (BMI) of 40 or higher (obesity class 3) are at a greater risk of infection than patients with […]
At the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025), a new pilot program debuted to educate and empower the next generation of clinicians treating patients with relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL).
Elias Jabbour, MD, leukemia professor at the University of Texas MD Anderson Cancer Center, moderates a discussion on acute lymphoblastic leukemia (ALL) MRD-guided treatment with Aaron Logan, MD, PhD, from the University of California, San Francisco, and Ibrahim T. Aldoss, MD, from the City of Hope.
This Meet the Professor session was delivered by Uma Borate, MD, MS, an associate professor at the Ohio State University Comprehensive Cancer Center, at SOHO 2025.
The study, presented by Guillermo Garcia-Manero, MD, interim chair of the Department of Leukemia at the University of Texas MD Anderson Cancer Center, evaluated the efficacy and safety of venetoclax in combination with azacitidine in treatment-naive patients with high-risk MDS.
